They saved a lot of shareholder's money by abandoning trials at this point. I've seen many companies irresponsibly push on with trials with lesser chances. At least they are conscientious. Maybe we are near bottom and ready to recover some.
ARQL did not abandoning MARQUEE clinical trials. It stopped the official part of it.The trial will be unblinded with patients and their doctors knowing who got what.
20% of all patients are still taking medication and will continue to do so.
ARQL will continue to follow MARQUEE patients and will continue to analyze the data as data are coming in.
This trial was poorly designed and poorly executed. Patients were not tested and down-selected for c-Met+ values as Roche does in their Metmab NSCLC trial.Now, ARQL nby now knows it was a big mistake and in future trials only c-Met+ patients will be enrolled.
Almost all biotech and Big Pharma have their share of failed trials. The failed trial does not mean the drug is bad. In the MARQUEE case, the drug was given to wrong patient population. The trial had 1,000 pts. So, we and scientific community will wait to see the data and data analysis.